Avalo Therapeutics (NasdaqCM:AVTX) FY Conference March 03, 2026 09:50 AM ET Company ParticipantsGarry Neil - CEOConference Call ParticipantsStacy Ku - Biotechnology Equity Research AnalystStacy KuThanks so much for joining our 46th Annual Healthcare Conference. I'm Stacy Ku, part of the biotech team with my colleague, Vi Shah, and we're very happy to be hosting Avalo Therapeutics. With us today, we have Garry Neil, CEO, and in the crowd joining us is CFO, Chris Sullivan. Really thanks to everyone for coming ...

Summary of Jack Henry & Associates FY Conference Call Company Overview - Jack Henry & Associates operates in the technology sector, providing solutions for banks and credit unions, including core processing, payment solutions, and complementary services. The company is celebrating its 50th anniversary and 40th year as a publicly traded entity [4][4]. AI Opportunities and Risks - The company views AI as more of an opportunity than a threat, having utilized AI for approximately 3.5 years. They have developed over 100 approved AI tools and identified more than 500 use cases, leading to significant improvements in various operational areas, including a 70% increase in development execution [7][8][10]. - Jack Henry has integrated AI into its operations with a focus on a balanced approach involving risk management and regulatory compliance [7][12]. Pricing Model - Jack Henry does not utilize seat-based licensing. Core contracts typically last 6-7 years, while payment and complementary product contracts last 3-5 years. Most contracts are account-based priced [13][14][16]. Bank Tech Spending Environment - Recent surveys indicate an increase in bank tech spending, with expectations of a 5-10% increase in 2026, up from 3-5% in previous years. Approximately 84% of banks and 83% of credit unions anticipate increased spending [20][23][24]. Core Segment Performance - Jack Henry reported 22 new competitive core wins in the last quarter, up from 11 the previous year, with 8 wins from a key competitor undergoing consolidation. The company has over 110 opportunities in its core pipeline [29][32][36]. - The average asset size of clients has increased from $750 million to $1.4 billion over the past several years, reflecting a strategic focus on larger financial institutions [50][50]. Trifecta Wins - The company has seen an increase in trifecta wins (core, digital banking, and card products), with a 68% attach rate compared to 45% the previous year. All 22 core wins included the Banno digital banking product, and 15 included card services [52][55][57]. Payments Segment Growth - The payments segment is evolving, with significant growth in faster payments solutions like Zelle and FedNow. Jack Henry has around 500 clients using these services, representing 33%-40% of the total population of FedNow and Clearing House networks [84][86]. - The company has introduced new solutions, including a merchant acquiring solution and real-time payment capabilities, which are expected to drive future revenue growth [87][89][92]. Banno Product Growth - Banno has grown rapidly, with over 15 million users and 1,037 banks and credit unions live on the platform. The mix between retail and business clients is approximately 45% business [96][96]. Capital Allocation Strategy - Jack Henry has a strong balance sheet with zero debt and plans to continue aggressive stock buybacks, having already exceeded its $200 million buyback target for the year. The company remains open to acquisitions that align with its technology strategy [98][99][102]. Conclusion - Jack Henry & Associates is positioned for growth through innovation in AI, a strong pipeline in core and payments segments, and a focus on larger financial institutions. The company is actively managing its capital allocation to enhance shareholder value while exploring strategic acquisitions.

Grainger Conference Call Summary Company Overview - Grainger is the largest distributor of maintenance, repair, and operating (MRO) products in North America, founded in 1927 with nearly 25,000 employees serving over 4.6 million customers [2][3] - The company operates two primary go-to-market models: High-Touch for larger customers and Endless Assortment for small to mid-sized businesses [4][5] Key Business Models - **High-Touch Model**: - Accounts for 80% of total revenue - Focuses on larger, complex customers with deep product knowledge and strong relationships [4] - **Endless Assortment Model**: - Accounts for 20% of total revenue - Targets small and mid-sized businesses with a simpler purchasing process [4][5] Market Position and Growth - Grainger holds a 7% market share in the High-Touch segment, indicating significant growth potential [5] - The Endless Assortment segment has doubled its revenue over the past five years, nearing $4 billion annually [11] - The company expects total revenue for 2026 to be between $18.7 billion and $19.1 billion, with organic sales growth of 6.5%-9% [12] Financial Performance - High-Touch has outgrown the broader MRO market by over 500 basis points in the last decade [11] - Expected EPS for 2026 is between $42.25 and $44.75, reflecting a 10% increase at the midpoint [13] - Operating margin is projected to improve by 40 to 90 basis points due to exiting the U.K. market and recovering gross margins [12][13] Strategic Initiatives - Investment in data and technology capabilities to enhance customer service and operational efficiency [6] - Development of AI and machine learning models to improve product offerings and marketing effectiveness [7][8] - Focus on supply chain optimization to ensure timely product delivery and high order accuracy [8][9] Competitive Advantages - Grainger's extensive product selection and supply chain capabilities position it well against competitors, even with the rise of AI-driven purchasing agents [30] - The company emphasizes a purpose-driven culture, known as the Grainger Edge, which fosters strong relationships with customers and suppliers [10][16] Challenges and Considerations - The company is monitoring tariff impacts on pricing and product costs, particularly concerning private label products [24][25] - Grainger's growth strategy includes selective M&A opportunities, focusing on enhancing its High-Touch and Endless Assortment businesses [32] Conclusion - Grainger is well-positioned for future growth, leveraging its strong market presence, innovative technology, and commitment to customer service to drive shareholder value [15][16]

Summary of Disc Medicine FY Conference Call Company Overview - **Company**: Disc Medicine (NasdaqGM:IRON) - **Focus**: Development of therapies targeting red blood cell disorders through manipulation of iron and heme metabolism [2][3] Key Clinical Programs 1. **Bitopertin for Erythropoietic Protoporphyria (EPP)** - Selected for the Commissioner's National Priority Voucher program - Received a Complete Response Letter (CRL) from the FDA; the next step is the Phase 3 trial (APOLLO) data expected in Q4 2026 [4][5] - Anticipated approval by mid-2027 based on APOLLO trial results [14][16] 2. **DISC-0974 for Anemia of Myelofibrosis** - Aims to mobilize iron to treat anemia; pivotal trial design expected by the end of 2026 [5][6] - Phase 2 data shows significant potential with a 50% major response rate in patients [21][25] - Addressable market in the U.S. estimated at 22,000 patients, with a total addressable opportunity of over $4 billion [20] 3. **DISC-3405 for Polycythemia Vera (PV)** - Designed to restrict iron availability to control red blood cell production [27][28] - Phase 1 data indicates promising results; pivotal trial expected to start in the first half of 2027 [28][29] Financial Position - **Balance Sheet**: $791 million in cash, providing a runway into 2029 without assuming revenue from lead program approval [8][30] Market Potential - **Total Addressable Markets**: - EPP: Over $2 billion - Myelofibrosis: Over $4 billion - Polycythemia Vera: Over $7 billion [30] Regulatory and Development Challenges - The CRL for bitopertin highlighted the need for clinical benefit proof in the APOLLO trial [36] - The company is preparing for a Type A meeting with the FDA to discuss the CRL and trial design [34][35] Additional Insights - The company emphasizes capital efficiency and maintaining a lean operational structure while advancing drug development [63][65] - There is significant excitement within the patient community regarding the potential impact of their therapies [15] Conclusion Disc Medicine is positioned to address significant unmet needs in the treatment of red blood cell disorders with a robust pipeline and a strong financial foundation, despite facing regulatory hurdles. The upcoming data readouts and trial designs will be critical in shaping the company's future trajectory and market entry strategies.

Summary of The Cheesecake Factory FY Conference Call Company Overview - **Company**: The Cheesecake Factory Incorporated - **Ticker**: NasdaqGS:CAKE - **Industry**: Casual Dining - **Key Brands**: The Cheesecake Factory, North Italia, Flower Child - **Current Locations**: 216 The Cheesecake Factory restaurants in the U.S. and Canada, 35 international locations under licensing agreements [3][46] Core Insights and Arguments - **Experiential Dining Leader**: The Cheesecake Factory is positioned as a leader in experiential dining, emphasizing unique guest experiences as a competitive advantage [2] - **Operational Excellence**: The company boasts industry-leading retention rates and experienced management, contributing to improved operational execution and solid financial results [2][10] - **Free Cash Flow Generation**: The company generates meaningful free cash flow, allowing for business investments and shareholder returns through dividends and share repurchases [3][41] - **Growth Potential**: The Cheesecake Factory aims to expand to 300 domestic locations, with North Italia targeting 200 and Flower Child aiming for 700 locations over time [3][46] Financial Performance - **2025 Financial Highlights**: - Adjusted EBITDA: $354 million - Cash flow from operating activities: over $301 million - Shareholder returns: more than $206 million through dividends and share repurchases [41][42] - **Sales Growth**: - The Cheesecake Factory: 1% increase in total sales - North Italia: 15% total sales growth - Flower Child: 28% sales growth [42][43] Menu and Innovation - **Menu Diversity**: The Cheesecake Factory offers over 225 menu items, with a focus on culinary innovation and seasonal updates [8][9] - **New Offerings**: Introduction of new categories like Bowls and Bites, which have shown strong initial interest and improved sales [9] - **Dessert Sales**: Industry-leading dessert sales at approximately 17%, with a focus on quality control and innovation in dessert offerings [10] Marketing and Brand Engagement - **Brand Affinity**: The Cheesecake Factory has built strong brand affinity through word-of-mouth and social media, with a significant presence on platforms like Instagram [11][12] - **Cultural Influence**: The brand has achieved a cult status, being referenced in various media and pop culture, enhancing its visibility and appeal [12] Future Outlook - **Revenue Projections**: Anticipated total revenues for 2026 are approximately $3.9 billion, with a net income margin target of around 5% [44] - **Unit Growth Strategy**: Expected long-term annual unit growth of 7%, positioning the company for significant expansion in the casual dining sector [45] - **Expansion Opportunities**: Potential for over $5 billion in additional revenue through expansion of existing brands and new concepts [47] Conclusion - **Competitive Position**: The Cheesecake Factory is well-positioned for long-term growth with a diversified portfolio, strong operational execution, and a focus on enhancing guest experiences [47][48]

Keros Therapeutics Conference Call Summary Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the TGF-beta pathway, which is crucial for embryogenesis and adulthood. An imbalance in this pathway can lead to various diseases [2][19]. Pipeline and Product Candidates - The lead asset is rinvatercept (KER-065), currently entering phase 2 trials for Duchenne Muscular Dystrophy (DMD) and Amyotrophic Lateral Sclerosis (ALS). A partnered asset with Takeda is in phase 3 trials [3][19]. - KER-065 is designed to inhibit myostatin and activin, which negatively regulate skeletal muscle and bone, thereby improving muscle regeneration and reducing fat mass [4][6]. - The company is also developing treatments for neuromuscular and neurodegenerative diseases, bone disorders, fibrosis, obesity, and frailty [19]. Clinical Data and Efficacy - Preclinical and phase 1 data suggest that KER-065 can treat a broad range of neuromuscular indications, particularly DMD, by increasing muscle mass, bone health, and reducing fat mass [6][11]. - In phase 1 studies, KER-065 was well-tolerated with no dose-limiting toxicities or bleeding events, which were concerns with earlier generation treatments [10][12]. - The treatment showed increases in lean mass and improvements in bone mineral density, which are critical for DMD patients who often suffer from osteoporosis [11][12]. ALS Treatment Approach - KER-065 aims to preserve muscle function in ALS patients by strengthening innervated muscles, potentially countering muscle atrophy [14][17]. - The company plans to initiate regulatory interactions for the ALS trial design in the second half of the year [15]. Market Opportunity and Strategy - Approximately 60% of DMD patients are only receiving glucocorticoids, presenting a significant opportunity for KER-065 to provide additional benefits [31][71]. - The company is considering a two-cohort approach for DMD trials, focusing on late ambulatory and early non-ambulatory patients [51][82]. Regulatory Considerations - The primary endpoints for upcoming trials will focus on safety and functional benefits, with imaging techniques used to assess changes in muscle and fat mass [98][105]. - The FDA has indicated that improvements in bone mineral density could serve as an approvable endpoint for osteoporosis treatments, which may apply to KER-065 [120]. Underappreciated Aspects - The company believes it is not receiving adequate credit for its elritercept program, which has shown efficacy in phase 2 trials for conditions like myelodysplastic syndrome and myelofibrosis [151][156]. - Keros Therapeutics is currently trading below cash value, indicating a potential undervaluation in the market [156]. Conclusion - Keros Therapeutics is positioned to address significant unmet needs in neuromuscular diseases with its innovative therapies, particularly KER-065, which has shown promising preclinical and early clinical results. The company is actively working on trial designs and regulatory strategies to maximize the potential of its product candidates.

Summary of Schrödinger FY Conference Call - March 03, 2026 Company Overview - **Company**: Schrödinger (NasdaqGS:SDGR) - **Industry**: Healthcare, specifically computational chemistry and drug discovery Key Points and Arguments Transition to Hosted Services - Approximately 25% of Schrödinger's revenue is now from hosted services, which allows for better customer support and monitoring of software usage [13][14] - Revenue recognition for hosted services occurs ratably over the contract term, contrasting with on-premise services where revenue is recognized upon closing [14] - The transition to hosted services is expected to temporarily reduce revenue for the current year, but deferred revenue will be recognized in the following year [19][20] Advances in Computational Chemistry - Significant advancements in computational chemistry allow Schrödinger to run calculations that can replace traditional experiments, generating data at a scale 10 years faster than experimental methods [30] - The integration of AI with computational chemistry enhances the ability to explore vast chemical spaces, improving the probability of success in drug development [30][31] - Schrödinger has produced 16 clinical assets, with a success rate better than the industry average [31] Predictive Toxicology - The predictive toxicology offering has exited beta testing with positive feedback and is expected to drive growth [56] - This tool addresses a major challenge in drug discovery by predicting toxicity early in the development process, potentially reducing reliance on animal testing [70][71] Growth Opportunities - Continued scale-up of technology usage among pharmaceutical companies is anticipated, which will drive growth [58] - Expansion into biologics and material science applications, including battery chemistry, is also a focus area for growth [59][60] - The introduction of a large molecule offering is expected to attract interest from companies working with ADCs and peptides [61] Partnership Strategy - A new partnership with TuneLab at Lilly aims to provide biotechs access to machine learning-trained toxicity models, enhancing the value of Schrödinger's offerings [94][95] - The partnership strategy is designed to enable users to become power users, increasing throughput and expanding the user base [97] Therapeutics Pipeline - Schrödinger is focused on advancing its therapeutics pipeline, with updates expected on SGR-3515 and SGR-1505 in the near future [100] - The company is excited about collaborations that generate IP and development candidates while also accruing royalties from successful programs [101] Market Position and Challenges - There is a disconnect in understanding the value of Schrödinger's platform due to the noise from numerous companies claiming to revolutionize drug discovery with AI [108] - The emphasis is on the company's track record of producing clinical assets and maintaining high customer retention [110][111] Conclusion - Schrödinger is positioned for growth through its innovative computational chemistry platform, strategic partnerships, and a focus on predictive toxicology and biologics. The company aims to clarify its value proposition amidst a crowded market of AI-driven drug discovery claims [112][113]

Summary of Annexon Biosciences Conference Call Company Overview - **Company**: Annexon Biosciences - **Focus**: Targeting the classical pathway with a next-generation neuroinflammatory approach, addressing diseases with a commercial potential exceeding $10 billion and impacting over 10 million patients [1][2] Core Programs 1. **Geographic Atrophy (GA)** - Late-stage Phase 3 program demonstrating significant vision preservation, the only program to do so [2][5] - Phase 2 study involved 270 patients, showing 50%-60% protection in central retina at 12 months [6][11] - Primary endpoint for Phase 3 is best corrected visual acuity, with results expected at month 15 [10][11] 2. **Guillain-Barré Syndrome (GBS)** - Landmark Phase 3 win, with significant improvement in muscle strength and recovery rates [21][22] - Approximately 7,000 cases annually in the U.S. and 15,000 in Europe, with a high treatment rate [32] - Filed for global regulatory approval in Europe and preparing for the U.S. filing [21][26] 3. **ANX1502** - First-in-kind small molecule drug candidate targeting classical pathway, currently in proof of concept study [2][40] - Aimed at neuromuscular autoimmune diseases, providing a potential oral alternative to current IV therapies [40] Strengths and Opportunities - **Innovation**: Unique approaches in GA and GBS, not following a "me-too" strategy, aiming to change market outlook [3][4] - **Education**: High educational curve due to novel approaches, particularly in GBS where no placebo-controlled study had been conducted in over 50 years [3][4] - **Safety Profile**: Differentiated safety profile in GA, with no significant difference in conversion to wet AMD compared to other therapies [6][13] Market Dynamics - **Commercialization Strategy**: Focus on educating key treatment practices and enhancing disease awareness, particularly in GA [16][17] - **Pricing Strategy**: Analysts estimate therapy costs between $100,000-$150,000, justified by significant healthcare savings [37][38] - **Reimbursement**: Active engagement with payers to ensure formulary inclusion and reimbursement [36] Financial Position - **Cash Balance**: Over $200 million, with a runway extending into late 2027, covering key upcoming catalysts [49] Key Takeaways - **Platform Approach**: Consistency in understanding the classical pathway across various neuroinflammatory diseases is a core strength [51] - **Asymmetric Value**: Current valuation does not reflect the potential advancements and outcomes expected in the next 12 months [51] Conclusion Annexon Biosciences is positioned to make significant impacts in the neuroinflammatory landscape with its innovative therapies targeting GA and GBS, backed by a strong financial position and a clear commercialization strategy. The company is focused on educating the market and ensuring successful product launches while maintaining a differentiated approach in treatment mechanisms.

Summary of Orchestra BioMed FY Conference Call (March 03, 2026) Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Development of innovative medical technologies, particularly in the fields of hypertension and coronary artery disease through partnerships with established companies like Medtronic and Terumo [1][2] Key Programs and Developments AVIM Therapy - **Indications**: Targets hypertensive heart disease and coronary artery disease, utilizing a pacemaker for delivery [3][4] - **Market Opportunity**: Estimated over $17 billion annual global opportunity in treating hypertension within the pacemaker population [5] - **Clinical Trials**: Actively enrolling in the BACKBEAT pivotal trial for AVIM therapy, with a goal to complete enrollment in 2026 and data readout expected in 2028 [4][24] - **Mechanism**: AVIM therapy modulates blood pressure by shortening the timing of atrial and ventricular contractions, leading to immediate and sustained blood pressure reduction [16][17] - **Clinical Data**: Demonstrated significant reductions in systolic blood pressure (average drop of 15.5 mmHg) and improvements in diastolic function in patients with isolated systolic hypertension [20][22] VIRTUE Sirolimus AngioInfusion Balloon - **Product Description**: A first-of-its-kind non-coated drug-eluting balloon designed for coronary artery disease treatment, leveraging a proprietary sirolimus formulation [25][26] - **Market Shift**: The market is transitioning from permanent implants like stents to drug-coated balloons, with a significant opportunity in both coronary and peripheral artery disease [25][26] - **Clinical Trials**: Enrolling patients in a pivotal trial against Boston Scientific's AGENT balloon, aiming for non-inferiority and potential superiority [30][44] - **Performance Metrics**: Achieved a low target lesion failure rate of 2.8% at one year, indicating strong clinical outcomes [29] Financial Position - **Funding**: Well-capitalized through late 2027, with recent transactions bringing in additional capital, including $21 million from the sale of Vivasure and $35 million in tranche payments from partnerships [7][8] - **Royalty Structure**: Potential royalties of $500 to $1,600 per device sold by Medtronic, with significant revenue opportunities anticipated from AVIM therapy [14][15] Strategic Partnerships - **Medtronic**: A key partner, holding over 50% of the global pacing market, with exclusive rights to commercialize devices incorporating AVIM therapy [15][16] - **Terumo**: Holds a right of first refusal for the VIRTUE product, with a recent investment of $65 million [30][31] Market Trends and Insights - **Hypertension and Heart Failure**: Elevated systolic blood pressure is a major driver of heart failure progression, with AVIM therapy positioned as a preventive treatment for patients at risk [34][35] - **Drug-Eluting Balloon Market**: Increasing adoption of drug-coated balloons in coronary procedures, particularly in Europe and Asia, with a growing recognition of the need for differentiated products [41][42] Conclusion - **Outlook**: 2026 is positioned as a pivotal year for Orchestra BioMed, with significant clinical trials underway and a strong financial foundation to support growth and innovation in the medical device sector [31][32]

Summary of Immunome Conference Call Company Overview - **Company**: Immunome - **Focus**: Targeted oncology with a pipeline of differentiated products, including first-in-class and best-in-class therapies [2][3] Key Product: Varegacestat - **Description**: An oral gamma secretase inhibitor for treating desmoid tumors, with a once-daily dosing regimen [3][4] - **Clinical Data**: - Phase 3 RINGSIDE study showed: - 84% reduction in risk of progression (hazard ratio of 0.16) - 56% objective response rate - 83% median best tumor volume reduction [3][6] - **NDA Submission**: Planned for Q2 2026, with no anticipated roadblocks [4][10] - **Market Potential**: - Estimated 10,000-11,000 patients in the U.S. with desmoid tumors, with only 10% currently on gamma secretase inhibitors [9][22] - Potential to capture a significant share of the market, with a target of 3,000 patients translating to a billion-dollar annual revenue [22] Competitive Landscape - **Nirogacestat**: The only approved systemic therapy for desmoid tumors, approved in late 2023. Varegacestat offers a better pharmacokinetic profile and once-daily dosing compared to Nirogacestat [5][9] - **Market Dynamics**: - OGSIVEO's launch has faced challenges, potentially limiting market growth. Immunome aims to differentiate by emphasizing the benefits of varegacestat [22][23] ADC Portfolio - **Technology**: Immunome is developing a proprietary ADC payload (HC74) to overcome limitations of existing ADCs, such as therapeutic window and resistance pathways [10][13] - **Current ADCs**: - **IM-1021**: ROR1-targeted ADC in dose escalation, focusing on lymphoma [11][12] - **Upcoming ADCs**: Three additional ADCs expected to enter clinical trials in 2026, all utilizing HC74 technology [16][17] - **Market Strategy**: Emphasis on selecting appropriate targets and optimizing ADC design to enhance efficacy and reduce toxicity [34][35] Radiotherapy Program - **IM-3050**: FAP-targeted radiotherapy with an active IND, expected to dose the first patient soon [17][48] - **Market Opportunity**: FAP is expressed in 75% of solid tumors, presenting a significant potential market [48] Financial and Commercial Strategy - **Cost-effective Launch**: Plans for a lean commercial infrastructure with approximately 32-35 sales reps, focusing on maximizing patient benefit and adherence [28][29] - **Long-term Vision**: Immunome aims to build a comprehensive portfolio of breakthrough oncology therapies, with varegacestat as the first clinical success [17][49] Conclusion - **Investment Outlook**: Immunome is currently valued primarily on varegacestat, with significant potential for the ADC portfolio to contribute to future growth [49]